Literature DB >> 34322611

COVID-19 emergency in Sicily and intersection with the 2019-2020 influenza epidemic.

Fabio Tramuto1,2, Walter Mazzucco1,2, Carmelo Massimo Maida1,2, Giuseppina Maria Elena Colomba1, Daniela DI Naro1, Federica Coffaro1, Giorgio Graziano2, Claudio Costantino1,2, Vincenzo Restivo1,2, Francesco Vitale1,2.   

Abstract

Entities:  

Keywords:  Influenza; Italy; Molecular surveillance; SARS-CoV-2; Sicily

Year:  2021        PMID: 34322611      PMCID: PMC8283625          DOI: 10.15167/2421-4248/jpmh2021.62.1.1870

Source DB:  PubMed          Journal:  J Prev Med Hyg        ISSN: 1121-2233


× No keyword cloud information.
During the 2019-2020 winter season, the Northern Hemisphere was called to face the experience of a simultaneous epidemic of coronavirus disease 2019 (COVID-19) and seasonal influenza [1]. Recent studies have documented in SARS-CoV-2 positive patients, early in the COVID-19 pandemic, a co-infection with other respiratory pathogens, including influenza [2-4]. The potential occurrence of co-infection underscored the need for simultaneous detection and evaluation in order to improve the differential diagnosis in patients with acute respiratory syndromes [5]. In Italy, the SARS-CoV-2 epidemic started around mid-February 2020 in Lombardy (Northern Italy) and, since then, new cases of infection have been reported in a number of other northern Italian regions, such as Veneto, Emilia-Romagna, Piedmont, Liguria, and Marche. More in depth, following the detection of two imported cases involving Chinese travelers on January 31st, 2020 [6, 7], the first autochthonous patient affected by COVID-19 (“patient zero”) was identified on February 19, 2020 in a 38-year-old Caucasian male from Codogno town. On February 21, 2020 the first cluster of 16 Italian cases was reported in Lombardy, followed by a number of new notified cases exponentially growing, until when, on February 22nd, 2020, public health authorities established a “red zone” encompassing 11 municipalities to contain the epidemic. Thereafter, in a short time, the epidemic spread to the neighboring regions located in the northern and central part of the country [8, 9], with a substantially lower impact on the rest of the country. In Sicily, the largest and southernmost region of Italy, as well as the fourth most populated one, the first confirmed case of SARS-CoV-2 infection was a 65-year-old woman from Bergamo (Lombardy), who was already on holiday in Palermo city a couple of days before the detection of “patient zero” in Codogno. This subject showed symptoms possibly referring to COVID-19 on February 23rd, 2020 and tested positive at SARS-CoV-2 molecular investigation on February 24th, 2020, followed the day after by two of the other twenty-nine fellow companions. Nevertheless, the first Sicilian autochthonous SARS-CoV-2 cases occurred early in March, most of them in close association with individuals who had travelled to or returned back from Lombardy in the previous week. Early in the course of the outbreak, severe containment measures were adopted by the Italian government throughout the entire country, which resulted in lockdown restrictions since March 9, 2020. These measures determined different local patterns of viral spread and Sicily took a clear advantage of this provision, experiencing low incidence of COVID-19 in the first semester of pandemic [10]. Of interest, chronologically-speaking, the early phase of SARS-CoV-2 epidemic partially overlapped the latter part of the seasonal influenza outbreak, which is annually explored during the winter through a nationwide sentinel surveillance network (InfluNet) [11], to which the Sicilian Reference Laboratory belongs. However, to date, no official laboratory data have been made available in order to get a shot of the real beginning of the spread of SARS-CoV-2 in Sicily. Therefore, to gain further understanding on the local transmission of SARS-CoV-2, respiratory specimens routinely collected in the framework of the 2019-2020 seasonal influenza virus surveillance were retrospectively re-evaluated by molecular testing for SARS-CoV-2. To this end, 2,330 samples collected from patients presenting with Influenza-like illness, between October 2019 and February 2020, were analyzed by reverse transcriptase real-time PCR, targeting different segments of the N gene of the SARS-CoV-2 genome [12]. Briefly, collected data showed that none of these samples tested positive for SARS-CoV-2, documenting no co-infection with influenza virus and confirming at the same time that in Sicily there has not been any circulation of the pandemic virus prior to the first documented cases. As stated above, from an epidemiological point of view, in Italy SARS-CoV-2 spread in an asynchronous way, showing different local patterns either in terms of incidence rates or affected geographic areas. Our data confirmed that SARS-CoV-2 appeared in Sicily at a later stage of the outbreak documented in Italy and, according to severe containment measures adopted by the Italian government, slowly spread with low incidence. Nevertheless, despite the epidemiology of COVID-19 and of seasonal influenza is different, symptoms related to the two mentioned diseases overlap, and their confluence has been expected to result in higher morbidity and mortality rates, with additional stress to the entire public health system [13, 14]. Therefore, a widespread use of influenza vaccination has been promoted during the current season 2020-2021 in combination of containment measures (i.e. correct use of personnel protection equipment, hand washing, social distancing, etc.). At the midterm of the current surveillance season, we were able to demonstrate also in Sicily the dramatic global decline in influenza virus circulation, as clearly documented through the national virological surveillance networks in Italy [15] and elsewhere [16-18]. Lastly, the body of the previous evidences highlights the importance of molecular diagnostic testing for SARS-CoV-2 both to distinguish between influenza and COVID-19 in patients with acute respiratory illness, and to provide continuous surveillance and timely tracing to define and rapidly implement effective containment measures.
  11 in total

1.  Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens.

Authors:  David Kim; James Quinn; Benjamin Pinsky; Nigam H Shah; Ian Brown
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

2.  COVID-19 and flu, a perfect storm.

Authors:  Edward A Belongia; Michael T Osterholm
Journal:  Science       Date:  2020-06-12       Impact factor: 47.728

3.  The Dual Epidemics of COVID-19 and Influenza: Vaccine Acceptance, Coverage, and Mandates.

Authors:  Lawrence O Gostin; Daniel A Salmon
Journal:  JAMA       Date:  2020-07-28       Impact factor: 56.272

4.  SARS-CoV-2 and influenza virus co-infection.

Authors:  Elena Cuadrado-Payán; Enrique Montagud-Marrahi; Manuel Torres-Elorza; Marta Bodro; Miquel Blasco; Esteban Poch; Alex Soriano; Gaston J Piñeiro
Journal:  Lancet       Date:  2020-05-05       Impact factor: 79.321

5.  COVID-19 and the next influenza season.

Authors:  Benjamin D Singer
Journal:  Sci Adv       Date:  2020-07-29       Impact factor: 14.136

6.  Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy.

Authors:  M R Capobianchi; M Rueca; F Messina; E Giombini; F Carletti; F Colavita; C Castilletti; E Lalle; L Bordi; F Vairo; E Nicastri; G Ippolito; C E M Gruber; B Bartolini
Journal:  Clin Microbiol Infect       Date:  2020-03-27       Impact factor: 8.067

7.  Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe.

Authors:  Paola Stefanelli; Giovanni Faggioni; Alessandra Lo Presti; Stefano Fiore; Antonella Marchi; Eleonora Benedetti; Concetta Fabiani; Anna Anselmo; Andrea Ciammaruconi; Antonella Fortunato; Riccardo De Santis; Silvia Fillo; Maria Rosaria Capobianchi; Maria Rita Gismondo; Alessandra Ciervo; Giovanni Rezza; Maria Rita Castrucci; Florigio Lista
Journal:  Euro Surveill       Date:  2020-04

8.  Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy.

Authors:  Gianguglielmo Zehender; Alessia Lai; Annalisa Bergna; Luca Meroni; Agostino Riva; Claudia Balotta; Maciej Tarkowski; Arianna Gabrieli; Dario Bernacchia; Stefano Rusconi; Giuliano Rizzardini; Spinello Antinori; Massimo Galli
Journal:  J Med Virol       Date:  2020-04-10       Impact factor: 20.693

View more
  2 in total

1.  Multidimensional Frailty and Vaccinations in Older People: A Cross-Sectional Study.

Authors:  Nicola Veronese; Giusy Vassallo; Maria Armata; Laura Cilona; Salvatore Casalicchio; Roberta Masnata; Claudio Costantino; Francesco Vitale; Giovanni Maurizio Giammanco; Stefania Maggi; Shaun Sabico; Nasser M Al-Daghri; Ligia J Dominguez; Mario Barbagallo
Journal:  Vaccines (Basel)       Date:  2022-04-03

2.  Influenza Vaccination and COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study.

Authors:  Nicola Veronese; Lee Smith; Francesco Di Gennaro; Olivier Bruyère; Lin Yang; Jacopo Demurtas; Stefania Maggi; Shaun Sabico; Nasser M Al-Daghri; Mario Barbagallo; Ligia J Dominguez; Ai Koyanagi
Journal:  Vaccines (Basel)       Date:  2022-06-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.